AU2016225070A1 - Crystalline forms of a pyrrolopyridine compound - Google Patents

Crystalline forms of a pyrrolopyridine compound Download PDF

Info

Publication number
AU2016225070A1
AU2016225070A1 AU2016225070A AU2016225070A AU2016225070A1 AU 2016225070 A1 AU2016225070 A1 AU 2016225070A1 AU 2016225070 A AU2016225070 A AU 2016225070A AU 2016225070 A AU2016225070 A AU 2016225070A AU 2016225070 A1 AU2016225070 A1 AU 2016225070A1
Authority
AU
Australia
Prior art keywords
bromo
cyclopropanecarboxamide
aminopiperidin
pyridin
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016225070A
Other languages
English (en)
Inventor
Christopher M. Lindemann
Weidong Liu
Joseph LUBACH
Keith L. Spencer
Jeffrey Stults
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Array Biopharma Inc
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55521844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016225070(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Publication of AU2016225070A1 publication Critical patent/AU2016225070A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2016225070A 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound Abandoned AU2016225070A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562121396P 2015-02-26 2015-02-26
US62/121,396 2015-02-26
PCT/US2016/019904 WO2016138458A1 (en) 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound

Publications (1)

Publication Number Publication Date
AU2016225070A1 true AU2016225070A1 (en) 2017-09-07

Family

ID=55521844

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016225070A Abandoned AU2016225070A1 (en) 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound

Country Status (21)

Country Link
US (2) US20160251350A1 (cg-RX-API-DMAC10.html)
EP (1) EP3262042A1 (cg-RX-API-DMAC10.html)
JP (1) JP2018506562A (cg-RX-API-DMAC10.html)
KR (1) KR20170118762A (cg-RX-API-DMAC10.html)
CN (1) CN107406447A (cg-RX-API-DMAC10.html)
AR (1) AR103801A1 (cg-RX-API-DMAC10.html)
AU (1) AU2016225070A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017018230A2 (cg-RX-API-DMAC10.html)
CA (1) CA2976665A1 (cg-RX-API-DMAC10.html)
CL (1) CL2017002180A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017009662A2 (cg-RX-API-DMAC10.html)
CR (1) CR20170439A (cg-RX-API-DMAC10.html)
HK (1) HK1246786A1 (cg-RX-API-DMAC10.html)
IL (1) IL254115A0 (cg-RX-API-DMAC10.html)
MA (1) MA41599A (cg-RX-API-DMAC10.html)
MX (1) MX2017010888A (cg-RX-API-DMAC10.html)
PE (1) PE20171327A1 (cg-RX-API-DMAC10.html)
PH (1) PH12017501532A1 (cg-RX-API-DMAC10.html)
RU (1) RU2017133093A (cg-RX-API-DMAC10.html)
SG (1) SG11201706824TA (cg-RX-API-DMAC10.html)
WO (1) WO2016138458A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102405199B1 (ko) * 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
CN108721284A (zh) * 2010-11-16 2018-11-02 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合
CA2921956C (en) * 2013-08-22 2021-10-19 Genentech, Inc. Process for preparing (r)-5-bromo-4-(3-amino)piperidin-1-yl)-3-(cyclopropanecarboxamido)-1h-pyrrolo[2,3-b]pyridine
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds

Also Published As

Publication number Publication date
HK1246786A1 (zh) 2018-09-14
CN107406447A (zh) 2017-11-28
BR112017018230A2 (pt) 2018-04-17
CL2017002180A1 (es) 2018-03-16
IL254115A0 (en) 2017-10-31
KR20170118762A (ko) 2017-10-25
CR20170439A (es) 2018-01-08
PE20171327A1 (es) 2017-09-12
RU2017133093A (ru) 2019-03-26
EP3262042A1 (en) 2018-01-03
WO2016138458A1 (en) 2016-09-01
US20180282324A1 (en) 2018-10-04
US20160251350A1 (en) 2016-09-01
RU2017133093A3 (cg-RX-API-DMAC10.html) 2019-08-23
PH12017501532A1 (en) 2018-02-05
CA2976665A1 (en) 2016-09-01
AR103801A1 (es) 2017-06-07
MA41599A (fr) 2018-01-02
JP2018506562A (ja) 2018-03-08
CO2017009662A2 (es) 2018-02-28
MX2017010888A (es) 2017-12-15
SG11201706824TA (en) 2017-09-28

Similar Documents

Publication Publication Date Title
EP2448941B1 (en) Pyrazolopyrimidine jak inhibitor compounds and methods
EP2049546B1 (en) Dihydrofuro pyrimidines as akt protein kinase inhibitors
US9802888B2 (en) STAT3 inhibitors
AU2009204025B2 (en) Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AU2009204019B2 (en) Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
EP3560921B1 (en) Quinazoline compound, preparation method, application as pi3k inhibitor for the treatment of cancer, and pharmaceutical compostion thereof
US20180282324A1 (en) Crystalline forms of a pyrrolopyridine compound
EA028059B1 (ru) Твердые формы n-((s)-2,3-дигидроксипропил)-3-(2-фтор-4-йодфениламино)изоникотинамида
EP3119775B1 (en) Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
TWI695000B (zh) 用於抑制adam9活性之化合物、其醫藥組合物及其用途
US20150051217A1 (en) Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
WO2023057545A1 (en) Substituted chalcones
US20160152574A9 (en) Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
TWI588144B (zh) 作爲parp抑制劑的稠合四或五環吡啶並酞嗪酮
EP4729519A1 (en) Crystal form of enpp1 inhibitor
HK1150201A (en) Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
HK1150201B (en) Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
HK1149269B (en) Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application